Vedolizumab in the therapy of Crohn’s disease

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE I. V. F. a. s. a Ústav lékařské biochemie a laboratorní diagnostiky, 1. LF UK a VFN v Praze
Published in: Gastroent Hepatol 2015; 69(2): 146-150
Category: IBD: Review Article
doi: https://doi.org/10.14735/amgh2015146

Overview

Vedolizumab is a monoclonal IgG1 anti integrine antibody, which a few months ago was approved in the European Union for clinical practice use in the therapy of idiopathic bowel diseases. It is expected that this year vedolizumab will be available on the market in the Czech Republic. The clinical research called GEMINI II‑III proved that vedolizumab is a very effective drug in patients with moderate to severe Crohn’s disease. Significant advantages of vedolizumab therapy include high efficacy in patients failing on anti‑TNFα therapy, sustained response with increasing effect over time, minimal drug immunogenicity and high safety drug profile, which is caused by high selectivity for gastrointestinal tract. There are some disadvantages or uncertainties, which include a slow anti‑inflammatory therapeutic response, restricted effect on extraintestinal manifestations and limited potential for healing of perianal Crohn’s disease.

Key words:
vedolizumab –⁠ Crohn’s disease –⁠ biological therapy

Sources

1. Lukáš M. Současnost a budoucnost v léčbě Crohnovy nemoci. Gastroent Hepatol 2013; 67(4): 306 –⁠ 312.

2. Bortlík M. Vedolizumab –⁠ nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68(6): 481 –⁠ 484. doi: 10.14735/ amgh2014481.

3. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014; 2(5): 333 –⁠ 344. doi: 10.1177/ 2050640614550672.

4. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369(8): 711 –⁠ 721. doi: 10.1056/ NEJMoa1215739.

5. Sanborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353(18): 1912 –⁠ 1925.

6. Sands BE, Feagan BG, Rutgeerts P et al.Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147(3): 618 –⁠ 627. doi: 10.1053/ j.gastro.2014.05.008.